Furoscix is a prescription used to treat edema in adults with chronic kidney disease or chronic heart failure. This medication is the first at-home, wearable diuretic. Its single-use, on-body infuser delivers 30mg of furosemide in the first 60 minutes, then 12.5 mg per hour for the next four hours.

Medication Overview:
  • Brand Name: Furoscix
  • Generic Name: Furosemide
  • Treatment for: Edemas 
  • Manufacturer(s): scPharmaceuticals
  • FDA Approval: October 2022
Indicated ConditionIndicatedAgeDate Approved
EdemaTreatment of edema in adults patients with chronic heart failure or chronic kidney disease, including nephrotic syndrome.Adult2022
Warnings and Precautions:

See full prescribing information for complete boxed warning.

  • Fluid, Electrolyte, and Metabolic Abnormalities: Furosemide may cause fluid, electrolyte, and metabolic abnormalities such as hypovolemia, hypokalemia, azotemia, hyponatremia, hypochloremic alkalosis, hypomagnesemia, hypocalcemia, hyperglycemia, or hyperuricemia, particularly in patients receiving higher doses, patients with inadequate oral electrolyte intake, and in elderly patients. Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients. Serum electrolytes, CO 2, BUN, creatinine, glucose, and uric acid should be monitored frequently during furosemide therapy.
  • Worsening Renal Function: Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, discontinue furosemide.
  • Ototoxicity: Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported with furosemide. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. If the physician elects to use high-dose parenteral therapy, controlled intravenous infusion is advisable (for adults, an infusion rate not exceeding 4 mg furosemide per minute has been used.
  • Acute Urinary Retention: In patients with severe symptoms of urinary retention (because of bladder emptying disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can cause acute urinary retention related to increased production and retention of urine. These patients require careful monitoring, especially during the initial stages of treatment.
  • Incomplete Dosing: The on-body infuser should not be allowed to get wet from water or any other fluids (blood or drug product). Fluid contact with the circuit board can lead to device errors and premature termination of infusion. The on-body infuser is intended for use in a setting where the patient can limit their activity for the duration of administration. Certain patient movements may cause interruption of device adherence to skin and premature termination of infusion. The on-body infuser for Furoscix should only be used in patients who can detect and respond to alarms to ensure a complete dose is administered.
Dosage and Administration

See full prescribing information for important administration instructions. 

  • Single-use, on-body infuser: Delivers 30mg of furosemide in the first 60 minutes, then 12.5 mg per hour for the next four hours.

Furoscix is not for chronic use and should be replaced with oral diuretics as soon as practical.

Contraindications:
  • Furoscix is contraindicated in patients with anuria.
  • Furoscix is contraindicated in patients with a history of hypersensitivity to furosemide, any component of the Furoscix formulation, or medical adhesives.
  • Anuria
  • Hypersensitivity to furosemide, components of Furoscix formulation, or medical adhesives.
Drug Interactions:
  • Aminoglycoside antibiotics: Increased potential ototoxicity of the antibiotics. Avoid combination.
  • Ethacrynic acid: Risk of ototoxicity. Avoid combination.
  • Salicylates: Risk of salicylate toxicity.
  • Cisplatin and nephrotoxic drugs: Risk of ototoxicity and nephrotoxicity.
  • Lithium: Risk of lithium toxicity.
  • Renin-angiotensin inhibitors: Increased risk of hypotension and renal failure.
  • Adrenergic blocking drugs: Risk of potentiation.
  • Drugs undergoing renal tubular secretion: Risk of toxicity potentiation.
Adverse Reactions:
  • Fluid, electrolyte, and metabolic abnormalities (as mentioned under Warnings and Precautions)
  • Ototoxicity (as mentioned under Warnings and Precautions)
  • Gastrointestinal System Reactions: pancreatitis, jaundice (intrahepatic cholestatic jaundice), increased liver enzymes, anorexia, oral and gastric irritation, cramping, diarrhea, constipation, nausea, vomiting.
  • Systemic Hypersensitivity Reactions: severe anaphylactic or anaphylactoid reactions (e.g., with shock), systemic vasculitis, interstitial nephritis, necrotizing angiitis.
  • Central Nervous System Reactions: tinnitus and hearing loss, paresthesias, vertigo, dizziness, headache, blurred vision, xanthopsia.
  • Hematologic Reactions: aplastic anemia, thrombocytopenia, agranulocytosis, hemolytic anemia, leukopenia, anemia, eosinophilia.
  • Dermatologic Hypersensitivity Reactions: toxic epidermal necrolysis, Stevens-Johnson Syndrome, erythema multiforme, drug rash with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, exfoliative dermatitis, bullous pemphigoid, purpura, photosensitivity, rash.
  • Cardiovascular Reactions: orthostatic hypotension, increase in cholesterol and triglyceride serum levels.
  • Administration Site and Skin Reactions: erythema, bruising, edema, infusion site pain.
  • Other Reactions: glycosuria, muscle spasm, weakness, restlessness, urinary bladder spasm, thrombophlebitis, transient injection site pain following intramuscular injection, fever.
Examples of Furosemide in Guidelines:
  • Management of Dyspnea in Advanced Cancer
    • American Society of Clinical Oncology
    • Last Updated: November 2024
    • Evidence remains insufficient for a recommendation for or against the use of anti-depressants, neuroleptics, or inhaled furosemide for dyspnea.
  • Management of Adult Patients with Ascites Due to Cirrhosis
    • American Association for the Study of Liver Diseases
    • Last Updated: January 2023
    • First-line treatment of patients with cirrhosis and ascites consists of sodium restriction (88 mmol per day [2000 mg per day], diet education,) and diuretics (oral spironolactone with or without oral furosemide).
  • Heart Failure In the Post Acute and Long-Term Care Setting
    • The Society for Post-Acute and Long-Term Care Medicine
    • Last Updated: October 2024
    • Table 6. Clinical Events That Can Help to Identify Patients With Advanced HF. Recent need to escalate diuretics to maintain volume status, often reaching daily furosemide equivalent dose >160 mg/d, use of supplemental metolazone therapy, or both.

Please note: This article is current as of May 19, 2025. Consult our clinical guidelines library or drug information tool to ensure you always have the most up-to-date information.

Sign up for alerts to keep up with the latest guidelines and FDA-related guideline updates.

Copyright 2025 © Guideline Central, all rights reserved.